Form 4: Acrivon Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Sharon Shacham acquired 20,275 stock options in Acrivon Therapeutics on June 20, 2024.
Summary
- Sharon Shacham, a director of Acrivon Therapeutics, Inc. [ACRV], acquired 20,275 stock options on June 20, 2024.
- The exercise price of these options is $6.52.
- The options vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent upon continuous service.
- The expiration date for the options is June 19, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option acquisition. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Director Sharon Shacham acquired stock options. |
| 06/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.